Lantern Pharma Inc Share Price Today: Live Updates & Key Insights

Lantern Pharma Inc share price today is $2.17, up -1.39%. The stock opened at $2.12 against the previous close of $2.16, with an intraday high of $2.17 and low of $2.03.

Lantern Pharma Inc Share Price Chart

Lantern Pharma Inc

us-stock
To Invest in {{usstockname}}
us-stock

Lantern Pharma Inc Share Price Performance

$2.17 -0.0139(-1.39%) LTRN at 23 Mar 2026 02:02 PM Biotechnology
Lowest Today 2.03
Highest Today 2.17
Today’s Open 2.12
Prev. Close 2.16
52 Week High 5.74
52 Week Low 2.03
Day’s Range: Low 2.03 High 2.17
52-Week Range: Low 2.03 High 5.74
1 day return -
1 Week return -8.62
1 month return -18.05
3 month return -43.42
6 month return -50.71
1 year return -47.85
3 year return -52.3
5 year return -90.22
10 year return -

Lantern Pharma Inc Institutional Holdings

BIOS CAPITAL MANAGEMENT, LP 9.03

Vanguard Group Inc 3.43

Vanguard Total Stock Mkt Idx Inv 2.24

CM Management, LLC 2.01

Renaissance Technologies Corp 0.99

Geode Capital Management, LLC 0.87

Vanguard Institutional Extnd Mkt Idx Tr 0.73

Voss Capital LLC 0.45

Fidelity Extended Market Index 0.41

BlackRock Inc 0.39

Dimensional Fund Advisors, Inc. 0.35

Goss Wealth Management LLC 0.34

Westside Investment Management, Inc. 0.32

UBS Group AG 0.30

Citadel Advisors Llc 0.29

Susquehanna International Group, LLP 0.26

Horizon Asset Management Inc/ny 0.25

Horizon Kinetics Medical ETF 0.25

Bank of New York Mellon Corp 0.24

Davenport & Company LLC 0.21

State Street Corp 0.21

iShares Micro-Cap ETF 0.19

Blackrock Extended Mkt Fund CF 0.16

Northern Trust Corp 0.14

Atlantic Trust Group, LLC 0.14

Extended Equity Market Fund K 0.14

Fidelity Total Market Index 0.14

DFA US Small Cap I 0.11

Cetera Investment Advisers 0.11

Spartan Extended Market Index Pool F 0.10

Fidelity Series Total Market Index 0.10

DFA US Social Core Equity 2 Portfolio 0.09

Northern Trust Extended Eq Market Idx 0.08

NT Ext Equity Mkt Idx Fd - L 0.08

Fidelity Nasdaq Composite Index 0.06

NT Ext Equity Mkt Idx Fd - NL 0.06

Spartan Total Market Index Pool G 0.06

Vanguard Instl Ttl Stck Mkt Idx Tr 0.05

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

DFA US Core Equity Class F 0.03

Lantern Pharma Inc Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Lantern Pharma Inc Fundamentals

Market Cap 23.82 M

PB Ratio 2.4955

PE Ratio 0.0

Enterprise Value 11.89 M

Total Assets 25.57 M

Volume 44972

Lantern Pharma Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-15156718 -15.2M, FY22:-14087139 -14.1M, FY21:-12295100 -12.3M, FY20:-5908190 -5.9M, FY19:-2428185 -2.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:100654 0.1M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-4102 -0.0M, Q2/2025:-4501 -0.0M, Q1/2025:-4574 -0.0M, Q3/2024:null 0.0M, Q2/2024:-46266 -0.0M

Quarterly Net worth Q3/2025:-4177423 -4.2M, Q2/2025:-4331015 -4.3M, Q1/2025:-4536783 -4.5M, Q3/2024:-4505697 -4.5M, Q2/2024:-4959506 -5.0M

About Lantern Pharma Inc & investment objective

Company Information Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Organisation Biotechnology

Employees 24

Industry Biotechnology

CEO Mr. Panna Sharma

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Lantern Pharma Inc FAQs

What is the share price of Lantern Pharma Inc today?

The current share price of Lantern Pharma Inc is $2.17.

Can I buy Lantern Pharma Inc shares in India?

Yes, Indian investors can buy Lantern Pharma Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Lantern Pharma Inc shares in India?

You can easily invest in Lantern Pharma Inc shares from India by:

Can I buy fractional shares of Lantern Pharma Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Lantern Pharma Inc?

Lantern Pharma Inc has a market cap of $23.82 M.

In which sector does Lantern Pharma Inc belong?

Lantern Pharma Inc operates in the Biotechnology sector.

What documents are required to invest in Lantern Pharma Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Lantern Pharma Inc?

The PE ratio of Lantern Pharma Inc is N/A and the PB ratio is 2.50.